Equities Analysts Offer Predictions for CPRX Q4 Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Analysts at Zacks Research cut their Q4 2025 EPS estimates for shares of Catalyst Pharmaceuticals in a research report issued on Monday, November 24th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $0.32 for the quarter, down from their previous forecast of $0.43. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q3 2026 earnings at $0.59 EPS, Q4 2026 earnings at $0.61 EPS, FY2026 earnings at $2.31 EPS, Q3 2027 earnings at $0.66 EPS and FY2027 earnings at $2.62 EPS.

CPRX has been the subject of a number of other reports. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Citigroup raised their price target on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Oppenheimer restated an “outperform” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $32.67.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $23.43 on Thursday. The company has a market capitalization of $2.88 billion, a PE ratio of 14.20, a P/E/G ratio of 0.84 and a beta of 0.79. The company has a 50 day moving average price of $21.24 and a 200-day moving average price of $21.72. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter. The company had revenue of $53.11 million during the quarter. Catalyst Pharmaceuticals had a net margin of 37.36% and a return on equity of 40.78%.

Catalyst Pharmaceuticals declared that its board has initiated a stock buyback program on Wednesday, October 1st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase up to 8.3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 30,000 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $20.30, for a total transaction of $609,000.00. Following the completion of the sale, the insider directly owned 271,039 shares in the company, valued at $5,502,091.70. This represents a 9.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last three months, insiders sold 80,000 shares of company stock valued at $1,596,200. Insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Deerfield Management Company L.P. raised its holdings in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares in the last quarter. American Century Companies Inc. grew its position in shares of Catalyst Pharmaceuticals by 233.9% in the 2nd quarter. American Century Companies Inc. now owns 1,757,988 shares of the biopharmaceutical company’s stock worth $38,148,000 after buying an additional 1,231,419 shares during the last quarter. Nuveen LLC bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth approximately $17,185,000. MetLife Investment Management LLC lifted its position in Catalyst Pharmaceuticals by 963.5% during the first quarter. MetLife Investment Management LLC now owns 724,091 shares of the biopharmaceutical company’s stock valued at $17,559,000 after acquiring an additional 656,004 shares during the last quarter. Finally, Fundsmith LLP boosted its stake in Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after acquiring an additional 654,721 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.